biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Thoughts in Summary

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Dec 23, 2022 12:39pm

81 Views

Post# 35189780

RE:RE:RE:Some Thoughts in Summary

KayakerBC said about MTP at USD 2.8¢, "And what are the odds that's the bottom? Not good."

On the London Exchange, Midatech is essentially the same as on NASDAQ - 2.25 pence or CDN 3.7¢

On NASDAQ, as KBC states, the price is USD 2.8¢, which is CDN 3.8¢

BTI has to fall to less than 4¢ to be in line with the GB and USA share prices.

Using CDN 4¢ as an average for all shares, the current market cap is around CDN $44 million, just less than a tenth of that being Bioasis.

Bioasis remains overpriced compared to the other two listings.

JD Boomskid

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing